Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.43
-2.33 (-19.81%)
At close: Aug 13, 2025, 4:00 PM
9.42
-0.01 (-0.11%)
After-hours: Aug 13, 2025, 7:59 PM EDT
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $25.88M in the quarter ending June 30, 2025, with 481.73% growth. This brings the company's revenue in the last twelve months to $62.02M, up 161.81% year-over-year. In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%.
Revenue (ttm)
$62.02M
Revenue Growth
+161.81%
P/S Ratio
9.96
Revenue / Employee
$1,051,186
Employees
59
Market Cap
660.15M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ZVRA News
- 1 day ago - Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Zevra Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 9 days ago - Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call - GlobeNewsWire
- 16 days ago - Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 26 days ago - Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG) - GlobeNewsWire
- 4 weeks ago - Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism - GlobeNewsWire
- 2 months ago - Zevra Announces Final Results of 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 3 months ago - All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees - GlobeNewsWire